Alexs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. Ally brings to RAVen nearly a decade of administrative experience. Brian's primary responsibility at RA Capital is to manage the firm's IT Operations needs. Joel brings 40 years of BioPharma drug discovery and development experience to that role. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. Bracketts primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. Her contributions involve engagement with teams across RA Capital, including the processing of CDA's. Brett Scheller is a Compliance Officer at RA Capital Management. Sarah Reed is the General Counsel at RA Capital Management. Max DeNies is a Senior Associate with the TechAtlas division of RA Capital Management. TipRanks & Hedge Funds: TipRanks measures the performance of Peter Kolchinsky and other hedge fund managers based on information submitted to the SEC. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. Jaimie holds a BA in Biology Boston College, with Minors in Medical Humanities and Sociology, and a Master of Public Health from Boston University School of Public Health. Most importantly, this book describes concrete . Scott received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. Since 2002, he has been working in start-up pharma companies, including co-founding Thesan Pharmaceuticals and NeoKera, where he assumed responsibilities for all development activities, including regulatory affairs. Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. Samuel Chowdhury is a Software Engineerat RA Capital Management. Michael Varnum is a Research Assistant at RA Capital Management. Christys primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Michael holds a B.S. Prior to RAVen, Cosmas was an Entrepreneur in Residence at Third Rock Ventures and was part of the teams that built Asher Bio (cell targeted biologics for oncology/autoimmune diseases) and Septerna (GPCR focused drug discovery) as well as other NewCOs in development. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. Dan Marks is a Principal on the Venture Team at RA Capital Management. Joels first role in Biotech was as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. Asia Pacific +65 6212 1000. Jennas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Joey previously served as Private Client Associate at Bernstein Private Wealth Management. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. Brian previously worked at the Kraft Group LLC, where he led their system admin, network, and desktop engineering groups. Angela has a BA in Pre-Medicine and French Studies from the University of Minnesota. Jesse has more than a decade of discovery research and management experience, from early discovery through preclinical development. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. He is active in both public and private investments In biotechnology areas as diverse as drugs, medical devices, diagnostics, and life science tools. Find Peter Kolchinsky's contact information, phone numbers, home addresses, age, background check, white pages, resumes and CV, places of employment, social media profiles, photos and videos, public records, arrest records, work history, news and business records . He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Peter Kolchinsky Founder and CEO RA Capital Management. She has published over fifty papers in peer reviewed journals. In this role, he propelled the company to the next stage of growth and increased shareholder value by altering the course of this formerly research-based company to prioritize innovation, speed to commercialization, and culture transformation. Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Prior to Mirai Advisory, he held a Financial Analyst role at Wainwright Investment Counsel. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. Sarah is the only lawyer to have received the NVCAs Outstanding Service Award, for her leadership role in conceiving of and spearheading the NVCA Model Legal Documents. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. Emory has a BS from Vassar College and an MD from the Harvard-MIT Health, Science, Technology Program at Harvard Medical School. Michael Sherman is a Venture Partner at RA Ventures. In his most recent role as Entrepreneur In Residence and Head of Computation at RA Ventures (RAVen), Soumya Ray supported the creation of two RAVen-incubated newcos. Brian holds a BA in Politics from Princeton University and an MBA in Health Care Management from University of Pennsylvania. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. Most recently, he was Chief Technology Officer at Vor Bio where he built the technical operations team responsible for process development, analytical development, supply chain and manufacturing support of a CRISPR gene-edited HSPC product and oversaw the companys CAR-T efforts. Sophie was a principal investigator in the Early Phase Trials Team at GSTT and has extensive experience in the delivery of early to late phase oncology trials. He worked previously as the Director of Business Systems at Bain Capital Credit, and as a Senior Systems Analyst at eSecLending, LLC. Michael is the Chief Financial Officer at RA Capital Management. Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. He is an Enrolled Agent, admitted to practice before the IRS. He is also active in the firms outreach efforts, speaking frequently both at industry events and in classrooms. At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. Nate Davis is an Analyst on the Investment Team at RA Capital Management. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University. As Engagement Associate at RA Capital Management, Thomas Culman leverages qualitative and quantitative skills to manage a variety of educational, outreach, and advocacy-oriented projects. Prior to that, David worked as Director of Operations for Wingspan Investment Management, LP and held operations positions at Brencourt Advisors and Silver Point Capital, LP. Matthew Hammond is a Principal on the Investment Team at RA Capital Management. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. Erin Clutter is the Head of Graphics at RA Capital Management. Prior to Localytics, Matt served as software engineer at Mathworks. Josh is a Senior Research Assistant at RA Capital Management. They will discuss the origins and history . As Head of Vaccines, he is leading the RA vaccine team to support our evidence-based investment strategy. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the companys inception in 2017 until its acquisition by Eli Lilly in 2021. However he's a bit older than others, like Raquel Leviss, who is only 28 . Maxs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Alexs primary responsibility at RA Capital is to partner with the Investment Team to develop quantitative analyses to support investment decisions and inform portfolio management. Before entering the life science space, Kat held various accounting roles in the retail industry and started her career at Ernst & Young. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. Rebecca conducts due diligence on biotechnology companies at RA Capital. Most of Joels career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last five years as Vice President and Global Head of Discovery Chemistry, working across all therapeutic areas. Cony received a BSc in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK. Brigid holds a BS in Chemistry (Hons) from the Commonwealth Honors College at the University of Massachusetts, Amherst (2002) and a PhD in Materials Science and Engineering from Johns Hopkins University (2009). The film delves into the psychological roots of Hook's anger, Peter Pan's everlasting childhood, and Wendy's reluctance to face adulthood. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. At Corning, he held a number of sales and marketing roles with increasing responsibility; in his last position at Corning, Cony was responsible for marketing at a new business unit focused on high-throughput screening and molecular biology products. Zach holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington. Michael conducts due diligence on biotechnology companies at RA Capital. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. View Profile. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. Matt Beverly is a Senior Software Engineer at RA Capital Management. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. Previously, Nate covered atopic dermatitis, psoriasis, dermatology, colorectal cancer, cancer diagnostics, and broader tools and diagnostics as a Senior Associate within RAs TechAtlas division. Sophie led the cell therapy program, working with teams across the Trust to build capabilities to deliver industry and academically sponsored complex cell therapy trials for solid tumor cancer patients. His graduate research investigated innate immune responses after intracerebral hemorrhage. Pieter holds a BA from Trinity College and a JD from Yale Law School. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. Lucas primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). Prior to RA, she served as Researcher and Collaborator at New Care, a startup focused on improving access to early childcare for lower income families. He holds a BA from Cornell University and a PhD in Virology from Harvard University. In his most recent role as Entrepreneur In Residence at RA Ventures (RAVen), Michael worked closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. Chriss primary responsibility at RA Capital is to cover the biotech and pharma industry. His laboratory at the Broad focused on advanced high throughput biotechnology tools including DNA synthesis, single cell analysis, synthetic biology derived biomolecule libraries, and microbiome profiling. Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. Jessica Sagers is Head of Engagement at RA Capital Management. Chris primary responsibility at RA Capital is to oversee the firms information technology program, including operations, development, and security. Cristinas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. He holds a BS in Finance from Providence College. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. Steve's survey is fascinating. She is a Clinical Reader at Kings College London with a laboratory working on translational adaptions to CAR T cell engineering to optimize clinical utility. Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products. During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. Ally Boertzel is an Executive Assistant at RA Ventures (RAVen). Abhishek is a Data Analyst Associate at RA Capital Management. May 27, 2022 (This is a long piece; click here to read it in Bionic Reading format, which may for some increase reading speed and comprehension. Priscilla Lee is an Associate within the TechAtlas division of RA Capital Management. Jacquelines primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. Asthas previous experience includes Research Assistant roles at Clark University and Corbus Pharma. Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Mariagrace Houllahan is an Executive Assistant at RA Capital Management. Shannon has a BA in Special Education and English from Bridgewater University and a MS in Elementary Education from Boston College. Kate previously served as Health Law Assistant at Mintz. Tom is a Senior Operations Analyst at RA Capital Management. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Emily Greenis a Visual Identity Designer at RA Capital Management. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. Christinas previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. Elena Forchielli is an Associate within the Planetary Health division of RA Capital Management. Within the last 20 years alone, PJ Hogan had a go with 2003's Peter Pan (a major, almost $100m-losing flop), Joe Wright tried again in 2015 with the more radical Pan (another massive failure . Join Peter Kolchinsky on his first episode of Future in Sight, a new podcast from FARE. Craig is admitted to practice law in the Commonwealth of Massachusetts. Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Ed holds a PhD in neuroscience from the University of California Berkeley, an MS in psychology from Villanova University, and a BA from La Salle University. Daphne Zohar is the founder and CEO of PureTech. He worked previously as a Patient Coordinator at Massachusetts General Hospital. Kate McKenna is a Compliance Associate at RA Capital Management. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. David is Director of Treasury at RA Capital Management. James was a post-doctoral fellow at Massachusetts Institute of Technology and University of California, Berkeley. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst. Monicas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Jacqueline is an Associate, Strategic Finance at RA Capital Management. Ed Monaghan is an EIR at RA Capital. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Katherine has a as a BA in Mathematics and a Minor in Chemistry from Boston College and a Master of Science in Medical Science from Boston University School of Medicine. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. Chris Morrison is an Editor at RA Capital Management. as a Staff Accountant. Kats primary responsibility is supporting newcos, portfolio companies and executives within RAVen, focusing on strategic finance. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. Peter conducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. He was also a Board Member of the Fannie & John Hertz Foundation and served as a judge for the Lemelson-MIT StudentPrize for Inventorship. Josh was previously co-lead of SV Health Investors US Biotech practice where he was responsible for SVs US venture creation activities, including its incubator, Brahma Discovery. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. Michael holds a BS in Exercise Science from Brigham Young University and an MD from the University of Texas Southwestern School of Medicine. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. She received a BA from Princeton University and an MBA from Harvard Business School. Bens primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. Jessica manages RA's Innovator Resources and co-founded RApport, our biotech communications platform. Prior to joining RA Capital and Arcuate Therapeutics, Tim was President and CEO of Proteon Therapeutics, a company focused on developing novel therapeutics to improve the lives of patients with kidney and vascular diseases. 1 reply 0 retweets 13 likes The market worked. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Michael is Executive Vice President at Capstan Therapeutics. She has spent the last five years as a Senior Finance Associate at Great Hill Partners. Megan has a BS in Microbiology & Cell Science from University of Florida. He holds Microsoft 365 and Microsoft certifications as Messaging Administrator Associate, Teams Administrator Associate, Teamwork Administrator Associate, and Azure Administrator Associate. The Kolchinskys came to the United States from Russia in 1981, when Peter was 4. Ernestos primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. He holds a BS in Computer Science from Northeastern University.
Bad Taste In Mouth Months After Tooth Extraction,
Articles P